AMT-151
/ Multitude Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
January 31, 2023
AMT-151 in Patients With Selected Advanced Solid Tumours
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: Multitude Therapeutics Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Metastases • Breast Cancer • Endometrial Adenocarcinoma • Endometrial Cancer • Endometrial Serous Adenocarcinoma • Hepatology • Lung Adenocarcinoma • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Triple Negative Breast Cancer
August 12, 2022
AMT-151 in Patients With Selected Advanced Solid Tumours
(clinicaltrials.gov)
- P1 | N=30 | Not yet recruiting | Sponsor: Multitude Therapeutics Inc.
New P1 trial • Breast Cancer • Endometrial Adenocarcinoma • Endometrial Cancer • Endometrial Serous Adenocarcinoma • Hepatology • Lung Adenocarcinoma • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Triple Negative Breast Cancer
1 to 2
Of
2
Go to page
1